Celltrion Gets Ready To Push Tocilizumab Into Phase III
Korean Company Offers Latest Details On Plans For Actemra/RoActemra Biosimilar
Celltrion has provided the latest update on progress for its CT-P47 proposed tocilizumab biosimilar, with Phase III trials set to begin for its rival to Actemra/RoActemra.
